C4 Therapeutics, Inc. (CCCC)
Nasdaq · Healthcare · Biotechnology
$2.99+1.36%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $368M
- 52-week range
- $1.69 – $5.17
- 52-week change
- +30.53%
- EPS (trailing)
- −$0.92
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $35.9M (+1.02%)
- Net income
- −$105M
- Operating margin
- −320.5%
- Diluted EPS
- −$1.27
- Free cash flow
- −$99.3M
From the company’s annual report on SEC EDGAR.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Headquarters: Watertown, United States · 104 employees · c4therapeutics.com